BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BAL0891 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BAL0891\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05768932-3042@assetmemo.bio
DTSTAMP:20261121T005413Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:BAL0891: Phase 1 readout est. (NCT05768932)
DESCRIPTION:BAL0891\, phase 1\, Acute Myeloid Leukemia.\nStudy: BAL0891 in 
 Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloi
 d Leukemia\nEstimated primary completion: 24 December 2026. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bal0891#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05768932
URL:https://assetmemo.bio/drug/bal0891#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
